Tavexia Lifecare fixes AGM date; seeks ₹100 crore RPT approval
- Tavexia Lifecare schedules 46th AGM for September 30, 2026
- Board seeks approval for ₹100 crore related-party transaction limit
- New statutory auditor DEVAM & Associates LLP appointed for five years
- Company plans to acquire up to 60% stake in Meyonex Pharmaceuticals

*this image is generated using AI for illustrative purposes only.
Tavexia Lifecare Limited has scheduled its 46th Annual General Meeting (AGM) for Wednesday, September 30, 2026, at 12:00 pm via Video Conferencing. The company has published the AGM notice in compliance with SEBI LODR Regulation 30, confirming the agenda includes adoption of FY25-26 accounts and special business items.
The meeting will address ordinary business including the adoption of FY25-26 accounts and special business involving auditor appointments and related-party transactions. The board previously announced plans to acquire up to a 60% stake in Meyonex Pharmaceuticals Limited. This acquisition proposal was approved during the board meeting on September 7, 2026.
Auditor and Board Changes
Tavexia accepted the resignation of its statutory auditors, M/s SSRV & Associates, effective September 7, 2026. The board appointed M/s DEVAM & Associates LLP as the new statutory auditors for a five-year term from FY27 to FY31, subject to shareholder approval at the upcoming AGM.
Additionally, the board recommended the reappointment of Mrs. Khushboo Vasudev as an independent director for a second five-year term starting December 31, 2026. This appointment also requires shareholder approval.
Related-Party Transaction Limits
The board seeks shareholder approval for material related-party transactions under Section 188 of the Companies Act, 2013. The proposed limit is up to ₹100 crore per related party for transactions including sale/purchase of goods, services, lending, and investments. This cap applies for an 18-month period from April 1, 2026, to September 30, 2027.
Key related parties include:
- Roshan Dealmark Private Limited (Promoter Company)
- Mayukh Trading Private Limited (Subsidiary Company)
- Mit Tarunkumar Brahmabhatt (Managing Director) and his relatives/entities
Key Financials of Target Entity
| Particulars | Details |
|---|---|
| Name | Meyonex Pharmaceuticals Limited |
| Authorized Capital | ₹20 crore |
| Paid-up Capital | ₹13.99 crore |
| Industry | Pharmaceuticals |
Corporate Governance Updates
The board took on record the secretarial audit report for FY25-26 from M/s Brajesh Gupta & Co. It also approved the Board Report, Corporate Governance Report, and Management Discussion and Analysis for the financial year ended March 31, 2026.
Mr. Brajesh Gupta was appointed as the scrutinizer for the e-voting process for the 46th AGM. The book closure period remains fixed from September 24, 2026, to September 30, 2026.
Historical Stock Returns for Sattva Sukun Lifecare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | -3.36% | +13.86% | +66.67% | +43.75% | -67.88% |
How might the acquisition of a 60% stake in Meyonex Pharmaceuticals impact Tavexia's revenue mix and market positioning in the pharmaceutical sector?
What are the strategic implications of granting a ₹100 crore related-party transaction limit, and how will this affect minority shareholder confidence?
Could the change in statutory auditors from SSRV & Associates to DEVAM & Associates signal any underlying governance or compliance concerns for FY25-26?


































